Alector (ALEC) Q4 2024 earnings summary

Executive summary

• Focused on developing first- or best-in-class disease-modifying therapies for neurodegenerative disorders, including FTD, Alzheimer's, and Parkinson's, with high unmet medical needs.

• Portfolio includes two late-stage clinical programs with GSK and five discovery programs leveraging proprietary Alector Brain Carrier (ABC) technology for enhanced brain delivery.

• Anticipates pivotal phase III trial readout for FTD with progranulin gene mutation in late 2025 and completion of patient recruitment for phase II AL101 Alzheimer's trial by mid-2025.

• Advancing preclinical pipeline using ABC technology, with lead candidates targeting amyloid beta and GCase.

• Strong cash position of $413.4 million as of December 31, 2024, expected to fund operations through 2026.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $413.4 million as of December 31, 2024.

• Q4 2024 collaboration revenue was $54.2 million, up from $15.2 million in Q4 2023; full-year 2024 revenue was $100.6 million, up from $97.1 million in 2023.

• Q4 2024 net loss was $2.1 million ($0.02 per share), a significant improvement from $41.4 million ($0.49 per share) in Q4 2023.

• Full-year 2024 net loss was $119.0 million ($1.23 per share), compared to $130.4 million ($1.56 per share) in 2023.

• R&D expenses for 2024 were $185.9 million, down from $192.1 million in 2023; G&A expenses for 2024 increased to $59.6 million from $56.7 million.

Outlook and guidance

• 2025 guidance: collaboration revenue $5–15 million; R&D expenses $175–185 million; G&A expenses $55–65 million.

• Expect significant milestones in 2025, including pivotal phase III data for FTD-GRN and completion of AL101 phase II enrollment.

• Plan to advance ABC-based programs to clinic in 2026.

• Cash runway expected to support operations through 2026.

• 2025 financial guidance reflects continued investment in pipeline and technology platforms.